Lupus Erythematosus, Systemic
Conditions
Brief summary
The study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of cevostamab in participants with systemic lupus erythematosus (SLE) with or without active lupus nephritis (LN).
Interventions
DRUGCevostamab
Participants will receive cevostamab IV as per the schedule given in the protocol.
DRUGTocilizumab
Tocilizumab may be used as rescue medication for participants who experience a cytokine release syndrome (CRS) event.
Sponsors
Genentech, Inc.
Study design
Allocation
NA
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Diagnosis of SLE according to the 2019 European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) Classification Criteria at least 6 months prior to the first screening visit * Active biopsy-proven LN established within 9 months of screening, demonstrating LN per 2018 Revised International Society of Nephrology/Renal Pathology Society (ISN/RPS) criteria * Diagnosis of active SLE disease, as demonstrated by the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score * Inadequate response or intolerance to, in the investigator's judgement, standard of care regimens for active SLE with or without LN
Exclusion criteria
* Pregnant or breastfeeding, or intending to become pregnant during the study or within the timeframe in which contraception is required * Treatment with investigational or non-investigational biologic therapies that directly deplete B cells (e.g., anti-CD20 or anti-CD19 monoclonal antibodies) (or blinded comparators) is prohibited within 6 months or 5 drug elimination half-lives, whichever is longer, prior to screening and during the study * Treatment with investigational biologic therapies that do not directly deplete B cells (or blinded comparators) is prohibited within 90 days or 5 drug elimination half-lives, whichever is longer, prior to initiation of study drug and during the study * Treatment of SLE/LN with non-investigational biologic therapies that do not directly deplete B cells (e.g., belimumab, anifrolumab) is prohibited within 4 weeks prior to screening and during the study * Treatment with CYC within 3 months prior to screening or during the study * History of known or suspected allergic reaction or anaphylactic reaction to cevostamab or its excipients * Major surgery requiring hospitalization during the 4 weeks prior to screening or during screening, or any planned surgery or procedure requiring hospitalization during the 12 weeks following study drug administration * Alcohol or substance abuse within the 12 months prior to screening * Active infection of any kind, excluding fungal infection of the nail beds * History of serious recurrent or chronic infection * Tuberculosis (TB) infection * Active overlap syndrome with mixed connective tissue disease or systemic sclerosis within the 12 months prior to screening or during screening * Catastrophic or severe antiphospholipid syndrome within the 12 months prior to screening or during screening * High risk for clinically significant bleeding or any condition requiring plasmapheresis, IV immunoglobulin, or acute blood product transfusions * Active severe or unstable lupus-associated neuropsychiatric disease, which, in the opinion of the investigator, is likely to require treatment with protocol-prohibited therapies * Non-SLE related CNS disease such as stroke, epilepsy, CNS vasculitis, or neurodegenerative disease
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percentage of Participants with Adverse Events (AEs) | Up to approximately 52 weeks |
Secondary
| Measure | Time frame |
|---|---|
| Serum Concentration of Cevostamab | Up to approximately 52 weeks |
| Area Under the Concentration-Time Curve (AUC) of Cevostamab | Up to approximately 52 weeks |
| Maximum Observed Serum Concentration (Cmax) of Cevostamab | Up to approximately 52 weeks |
| Minimum Observed Serum Concentration (Cmin) of Cevostamab | Up to approximately 52 weeks |
| Clearance (CL) of Cevostamab | Up to approximately 52 weeks |
| Volume of Distribution at Steady State (Vdss) of Cevostamab | Up to approximately 52 weeks |
| Change from Baseline in the Presence Anti-Drug Antibodies (ADAs) | Up to approximately 52 weeks |
Contacts
CONTACTReference Study ID Number: GA46280 https://forpatients.roche.com/ No attachments to email below.
CONTACTFastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
Outcome results
None listed